SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Liwing Johan)
 

Sökning: WFRF:(Liwing Johan) > Real-world study of...

Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease

Schain, Frida (författare)
Janssen Global Serv, Stockholm, Sweden.;Karolinska Inst, Div Hematol, Dept Med, Solna, Sweden.;Schain Res, Bromma, Sweden.
Batyrbekova, Nurgul (författare)
Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Scandinavian Dev Serv, Stockholm, Sweden.
Liwing, Johan (författare)
Janssen Global Serv, Stockholm, Sweden.;Karolinska Inst, Dept Med, Div Hematol, Huddinge, Sweden.
visa fler...
Baculea, Simona (författare)
Janssen Global Serv, High Wycombe, Bucks, England.
Webb, Thomas (författare)
Janssen Global Serv, High Wycombe, Bucks, England.
Remberger, Mats (författare)
Uppsala universitet,Hematologi,Uppsala Univ Hosp, KFUE, Uppsala, Sweden
Mattsson, Jonas (författare)
Karolinska Institutet
visa färre...
Janssen Global Serv, Stockholm, Sweden;Karolinska Inst, Div Hematol, Dept Med, Solna, Sweden.;Schain Res, Bromma, Sweden. Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Scandinavian Dev Serv, Stockholm, Sweden. (creator_code:org_t)
2020-12-04
2021
Engelska.
Ingår i: European Journal of Health Economics. - : Springer Nature. - 1618-7598 .- 1618-7601. ; 22:1, s. 169-180
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpatient visits), as well as indirect costs associated with sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT in Sweden between 2006 and 2015, linking population-based health and economic registers. To capture the period of chronic GVHD, patients were included who survived > 182 days post-HSCT (start of follow-up), and cGVHD was classified based on patient treatment records to correct for any diagnosis underreporting. Patients were classified as 'non-cGVHD' if they received no immunosuppressive treatment, 'mild cGVHD' if they received only systemic corticosteroid treatment or immunosuppressive treatment, or 'moderate-severe cGVHD' if they received extracorporeal photopheresis (ECP) only, corticosteroid treatment and immunosuppressive treatment, or systemic corticosteroid treatment and ECP treatments. Patients with moderate-severe cGVHD spent more time in healthcare, had higher healthcare resource costs and higher sickness absence-related productivity loss compared to patients with non- or mild cGVHD. The cumulative total costs during the first 3 years of follow-up were EUR 14,887,599, EUR 20,544,056, and EUR 47,811,835 for non-, mild, and moderate-severe groups, respectively. The long-term costs incurred with cGVHD following HSCT continue to be very high and significantly impacted by cGVHD severity. This study adds real-world health resource and economic insight relevant for policy-makers and healthcare providers when considering the clinical challenge of balancing immunosuppression to reduce cGVHD.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Chronic graft versus host disease
Economic burden
Direct medical costs
Indirect costs
Sweden

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy